Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer

Summary

Study objectives are to investigate the efficacy and safety of activated autologous dendritic cells (DCs) in treatment of gastric cancer. DCs are activated by the proteins from autologous tumor cell membrane and cytokines in vitro. The efficacy endpoints include objective response, immune-cell response, recurrent rate after a radical surgery, progression-free survival and overall survival, and the safety endpoints include adverse events, laboratory tests, ECG, ECOG-PT, etc.

Timeline

Start

2017-07-01

Primary completion

2020-07-01

Completion

2020-12-01

Drugs

Indications